Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection

Table 2 Patient characteristics at initiation of triple anti-hepatitis C virus therapy (n = 41)

Age: median (IQR)	51 (48-55)
Male gender	35 (85.4%)
Genotype
1a	32 (78.0%)
1b	9 (22.0%)
HCV treatment-naïve	13 (31.7%)
Prior HCV-treatment response
Non-responders	14 (34.1%)
Breakthrough	1 (2.5%)
Relapse	5 (12.2%)
Premature treatment discontinuation	3 (4.9%)
Missing data	5 (14.6%)
Log HCV-RNA	5.8 (5.3-6.1)
Fibrosis stage
F0-F1	12 (29.3%)
F2	7 (17.0%)
F3	5 (12.2%)
F4	17 (41.5%)
CD4 T-cells/mm3: median (IQR)	540 (441-782)
HIV-RNA < 40 copies/mL	41 (100.0%)

HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; IQR: Interquartile range.